- Home
- ATLO vs SGMT Comparison
ATLO vs SGMT Comparison
Compare ATLO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLO
- SGMT
- Stock Information
- Founded
- ATLO 1903
- SGMT 2006
- Country
- ATLO United States
- SGMT United States
- Employees
- ATLO N/A
- SGMT N/A
- Industry
- ATLO Major Banks
- SGMT
- Sector
- ATLO Finance
- SGMT
- Exchange
- ATLO Nasdaq
- SGMT Nasdaq
- Market Cap
- ATLO 144.8M
- SGMT 159.0M
- IPO Year
- ATLO N/A
- SGMT 2023
- Fundamental
- Price
- ATLO $17.69
- SGMT $4.13
- Analyst Decision
- ATLO
- SGMT Buy
- Analyst Count
- ATLO 0
- SGMT 6
- Target Price
- ATLO N/A
- SGMT $23.00
- AVG Volume (30 Days)
- ATLO 27.7K
- SGMT 1.2M
- Earning Date
- ATLO 01-28-2025
- SGMT 11-13-2024
- Dividend Yield
- ATLO 5.70%
- SGMT N/A
- EPS Growth
- ATLO N/A
- SGMT N/A
- EPS
- ATLO 0.98
- SGMT N/A
- Revenue
- ATLO $51,071,000.00
- SGMT N/A
- Revenue This Year
- ATLO N/A
- SGMT N/A
- Revenue Next Year
- ATLO N/A
- SGMT N/A
- P/E Ratio
- ATLO $17.71
- SGMT N/A
- Revenue Growth
- ATLO N/A
- SGMT N/A
- 52 Week Low
- ATLO $15.69
- SGMT $2.39
- 52 Week High
- ATLO $22.41
- SGMT $18.90
- Technical
- Relative Strength Index (RSI)
- ATLO 62.10
- SGMT 41.82
- Support Level
- ATLO $16.95
- SGMT $4.06
- Resistance Level
- ATLO $17.93
- SGMT $7.38
- Average True Range (ATR)
- ATLO 0.43
- SGMT 0.63
- MACD
- ATLO 0.17
- SGMT -0.11
- Stochastic Oscillator
- ATLO 87.30
- SGMT 2.11
About ATLO Ames National Corporation
Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).